FDA Says Vasopressin Wasn’t Pulled for Safety Reasons
Published Date: 7/6/2026
Notice
Summary
The FDA has confirmed that vasopressin in sodium chloride (0.9%, injection) wasn’t taken off the market because of safety or effectiveness problems. This means generic versions can now get approved if they meet all the rules, helping patients and healthcare providers get more options. No changes in price or availability are expected right now, but more generics could be coming soon!
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Generic Approvals Allowed for Vasopressin
On July 6, 2026, FDA determined that VASOPRESSIN IN SODIUM CHLORIDE (vasopressin) 0.9% injection, 50 units/50 mL (1 unit/mL) was not withdrawn from sale for reasons of safety or effectiveness. That determination allows abbreviated new drug applications (ANDAs) that reference this listed drug to be approved if they meet all other legal and regulatory requirements, which can permit generic versions to enter the market. The product was initially approved July 11, 2024 and Long Grove Pharmaceuticals notified FDA of discontinuation on May 9, 2025.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
Previous / Next Documents
Previous: 2026-13490, Seamless Carbon and Alloy Steel Standard, Line, and Pressure Pipe From the Republic of Korea and the Russian Federation: Final Results of the Expedited First Sunset Review of the Countervailing Duty Orders
The U.S. Department of Commerce decided to keep extra taxes (countervailing duties) on seamless steel pipes from Korea and Russia because removing them could bring back unfair government help to those countries’ pipe makers. This means importers will still pay these duties starting July 6, 2026, protecting U.S. steel producers like Vallourec. So, prices and trade rules stay steady to keep things fair and competitive.
Next: 2026-13493, Blue Tractor ETF Trust, et al.
Blue Tractor ETF Trust wants to update its investment rules to include more types of financial instruments, giving its funds more ways to grow your money. This change affects investors in their funds and could open up new opportunities starting soon. If anyone wants a hearing about this, they need to ask by July 27, 2026.